

Brad Poore

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10518351/publications.pdf>

Version: 2024-02-01

16
papers

800
citations

1162889

8
h-index

1281743

11
g-index

16
all docs

16
docs citations

16
times ranked

2010
citing authors

#	ARTICLE	IF	CITATIONS
1	Dysregulated metabolism contributes to oncogenesis. <i>Seminars in Cancer Biology</i> , 2015, 35, S129-S150.	4.3	225
2	Designing a broad-spectrum integrative approach for cancer prevention and treatment. <i>Seminars in Cancer Biology</i> , 2015, 35, S276-S304.	4.3	220
3	Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E5328-36.	3.3	180
4	Divergent paths for the selection of immunodominant epitopes from distinct antigenic sources. <i>Nature Communications</i> , 2014, 5, 5369.	5.8	62
5	Allosteric Glutaminase Inhibitors Based on a 1,4-Di(5-amino-1,3,4-thiadiazol-2-yl)butane Scaffold. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 520-524.	1.3	50
6	Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-Norleucine. <i>Clinical Cancer Research</i> , 2019, 25, 5925-5936.	3.2	22
7	Inhibition of mTORC1 in pediatric low-grade glioma depletes glutathione and therapeutically synergizes with carboplatin. <i>Neuro-Oncology</i> , 2019, 21, 252-263.	0.6	21
8	Molecular Heterogeneity and Cellular Diversity: Implications for Precision Treatment in Medulloblastoma. <i>Cancers</i> , 2020, 12, 643.	1.7	13
9	TORC1/2 kinase inhibition depletes glutathione and synergizes with carboplatin to suppress the growth of MYC-driven medulloblastoma. <i>Cancer Letters</i> , 2021, 504, 137-145.	3.2	5
10	OTME-9. Comprehensive Metabolic Profiling Of high MYC Medulloblastoma Reveals Key Differences Between In Vitro And In Vivo Glucose And Glutamine Usage. <i>Neuro-Oncology Advances</i> , 2021, 3, ii15-ii15.	0.4	1
11	Gamma Glutamyl Transferase Activity Has Limited Utility in Assessment of Alkaline Phosphatase Elevations. <i>Journal of Applied Laboratory Medicine</i> , 2021, 6, 1623-1627.	0.6	1
12	MBRS-61. IN VIVO METABOLOMICS REVEALS A POTENT COMBINATION THERAPY FOR MYC-DRIVEN MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, ii141-ii141.	0.6	0
13	ATRT-04. UNBIASED METABOLIC PROFILING OF ATYPICAL TERATOID/RHABDOID TUMORS PREDICTS SENSITIVITY TO GLUTAMINE METABOLIC INHIBITORS. <i>Neuro-Oncology</i> , 2019, 21, ii63-ii63.	0.6	0
14	Retrospective Evaluation of the Antibody Prevalence in Epilepsy and Encephalopathy (APE2) Score. <i>Journal of Applied Laboratory Medicine</i> , 2022, 7, 36-45.	0.6	0
15	FSMP-18. COMPREHENSIVE METABOLIC PROFILING OF HIGH MYC MEDULLOBLASTOMA REVEALS KEY DIFFERENCES BETWEEN IN VITRO AND IN VIVO GLUCOSE AND GLUTAMINE USAGE. <i>Neuro-Oncology Advances</i> , 2021, 3, ii19-ii19.	0.4	0
16	CSIG-21. BAF60C/SMARCD3 REGULATES TUMOR CELL DISSEMINATION IN MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, ii32-ii32.	0.6	0